Stryker corporation SYK.US Overview
SYK AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
SYK Current Performance
-0.03%
Stryker corporation
-2.38%
Avg of Sector
-0.30%
S&P500
SYK Key Information
SYK Revenue by Segments
Browsing restrictions can be lifted for a fee.
SYK Net Income
Browsing restrictions can be lifted for a fee.
SYK Cash Flow
Browsing restrictions can be lifted for a fee.
SYK Profit Margin
Browsing restrictions can be lifted for a fee.
SYK PE Ratio River
Browsing restrictions can be lifted for a fee.
SYK Financial Forecast
Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2025Q1 | ||||
| 2025Q2 | ||||
| 2025Q3 | ||||
| 2025Q4 | ||||
| 2026Q1 |
SYK Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
SYK Profile
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Price of SYK
SYK FAQ
When is SYK's latest earnings report released?
The most recent financial report for Stryker corporation (SYK) covers the period of 2025Q1 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating SYK's short-term business performance and financial health. For the latest updates on SYK's earnings releases, visit this page regularly.
Where does SYK fall in the P/E River chart?
According to historical valuation range analysis, Stryker corporation (SYK)'s current price-to-earnings (P/E) ratio is 50.56, placing it in the Watch zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning optimistic. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
What is the operating profit of SYK?
According to the latest financial report, Stryker corporation (SYK) reported an Operating Profit of 837M with an Operating Margin of 14.27% this period, representing a decline of 13.89% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is SYK's revenue growth?
In the latest financial report, Stryker corporation (SYK) announced revenue of 5.87B, with a Year-Over-Year growth rate of 11.88%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much debt does SYK have?
As of the end of the reporting period, Stryker corporation (SYK) had total debt of 16.78B, with a debt ratio of 0.36. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does SYK have?
At the end of the period, Stryker corporation (SYK) held Total Cash and Cash Equivalents of 2.32B, accounting for 0.05 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does SYK go with three margins increasing?
In the latest report, Stryker corporation (SYK) achieved the “three margins increasing” benchmark, with a gross margin of 63.8%%, operating margin of 14.27%%, and net margin of 11.1%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess SYK's profit trajectory and future growth potential.
Is SYK's EPS continuing to grow?
According to the past four quarterly reports, Stryker corporation (SYK)'s earnings per share (EPS) shows a declining trend, with the latest EPS at 1.71. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of SYK?
Stryker corporation (SYK)'s Free Cash Flow (FCF) for the period is 127M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 243.24% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of SYK?
The latest valuation data shows Stryker corporation (SYK) has a Price-To-Earnings (PE) ratio of 50.56 and a Price/Earnings-To-Growth (PEG) ratio of 2.77. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.